Related Experiment Video
Updated: Aug 6, 2026

Rose Bengal-Mediated Photodynamic Therapy to Inhibit Candida albicans
Published on: March 24, 2022
A multitarget ruthenium-clotrimazole complex eradicates MRSA through membrane disruption, DNA intercalation, and ROS
Xiaoyin Wu1, Jinhao Li1, Wentao Lei1
1Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Chemical Engineering, South China Agricultural University, Guangzhou 510642, China.
Abstract:
The escalating crisis of antibiotic resistance necessitates the development of agents with novel mechanisms. In this work, three novel ruthenium(II) complexes coordinated with imidazole-based ligands were reported. Among them, Ru-ctz demonstrated exceptional activity against methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) of 0.78 μM, greatly surpassing clotrimazole (MIC = 50 μM), and exceeding both vancomycin (MIC = 1.56 μM) and daptomycin (MIC = 3.12 μM). Mechanistic investigations revealed a synergistic multitarget action: Ru-ctz disrupts bacterial membrane integrity, induces lethal reactive oxygen species (ROS), and intercalates into genomic DNA. It also potently inhibits and eradicates biofilms while suppressing the virulence factor α-hemolysin. Notably, Ru-ctz demonstrated a minimal propensity for resistance development over 20 serial passages. Furthermore, in a murine MRSA skin infection model, Ru-ctz effectively accelerated wound healing and mitigated inflammation, showing good biocompatibility. With its multitarget mechanism, compelling in vitro and in vivo efficacy, and low resistance propensity, Ru-ctz is positioned as a promising therapeutic candidate for combating multidrug-resistant bacterial infections.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Antifungal Agents
Inhibitors of Bacterial DNA Synthesis
Gene Regulation in Microbial Communities: Quorum Sensing
Antimicrobial Effectiveness
